EPHX2 and diabetic kidney disease: Numerous researches have shown that either the genetic deletion or pharmacological inhibition of sEH can decrease blood pressure (24), suppress inflammatory response (5), attenuate histological damage, and alleviate the progression of renal tubulointerstitial fibrosis in diabetic nephropathy, hypertensive nephropathy, and unilateral ureteral obstruction models (6, 22, 23).